NEW YORK (GenomeWeb) – Molecular diagnostics firm Biocartis and Abbott today announced a collaboration to develop and commercialize companion diagnostic tests for use on Biocartis' Idylla system.

Under the terms of the deal, the firms will leverage Biocartis' and Abbott's regulatory, scientific, and commercialization expertise, and in partnership with pharmaceutical companies, they will create biomarker panels for use on Idylla where each biomarker in the panel has known clinical significance.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.